The relationship between mobocertinib and mobosetinib/mobotinib

Mobocertinib and mobocertinib/mobocertinib actually refer to the same drug, and the relationship between them is that they are different names for the same drug. This drug is a new, highly selective oral tyrosine kinase inhibitor (TKI), specifically targeting the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (EGFR ex20ins).

Specifically,Mobocertinib is the English name of the drug, while mobocertinib and mobocertinib are different translations of the drug in the Chinese environment. Among them, mobosetinib may be better known because it is the first and only oral TKI drug approved in China for EGFR ex20ins mutated NSCLC. The mechanism of action of mobosetinib is mainly by selectively inhibiting the activity of EGFR, thereby preventing the proliferation and growth of cancer cells.

The drug was developed and produced by Takeda Pharmaceuticals of Japan. It was approved for marketing by the Food and Drug Administration (FDA) in the United States on September 15, 2021. It was subsequently approved by the National Medical Products Administration in January 2023 and officially entered the Chinese market. Its indications are mainly for the treatment of adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations that have progressed during or after platinum-containing chemotherapy.

Clinical study results show that mobosetinib can significantly improve patients' median progression-free survival (PFS) and median overall survival (OS), while improving patients' quality of life. Although the drug also has some adverse reactions, most symptoms are effectively controlled under the management of a doctor. In addition, due to the heterogeneity of cancer, it is often difficult to achieve the desired effect with a single drug. Therefore, multiple factors will be considered in treatment selection, including the molecular characteristics of the tumor, the patient's physical condition, and the response to previous treatments.